Risk talk:: rhetorical strategies in consultations on hormone replacement therapy

被引:11
|
作者
Hoffmann, M
Linell, P
Lindh-Åstrand, L
Kjellgren, KI
机构
[1] Linkoping Univ, Dept Med & Care, Div Clin Pharmacol, SE-58183 Linkoping, Sweden
[2] Linkoping Univ, Dept Commun Studies, SE-58183 Linkoping, Sweden
[3] Linkoping Univ, Dept Mol & Clin Med, Div Obstet & Gynecol, SE-58183 Linkoping, Sweden
[4] Gothenburg Univ, Sahlgrenska Acad, Fac Hlth & Caring Sci, Inst Nursing, SE-40530 Gothenburg, Sweden
关键词
risk; communication; menopause; hormone replacement therapy; physician-patient relations;
D O I
10.1080/1369857031000123920
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
When analysing risk discussions in medical settings it is important to consider the specific activity type. In this qualitative study 20 first-time consultations by healthy women regarding hormone replacement therapy (HRT) in the menopause the risk discussion is asymmetrical with the doctors dominating. Despite being set up as a specific opportunity for women in the menopause to discuss problems and risks, it comes forth as a decision-making activity in a traditional medical setting. The consultations fulfil to a high extent the demands for informed decision making, but the risk discussions are recontextualised into a cost-benefit discourse with a typical implicit quantitative bias. The doctors use several different rhetorical strategies such as positive introduction of HRT, embedding drawbacks in positive introductions and/or exits thereby diminishing them. The word risk is avoided to a considerable extent and the term 'drawbacks' is used instead. The most obvious strategy is to move from the woman's symptoms to aspects of prevention, thus changing the discussion from the menopause and different strategies to cope with menopausal problems into a medically oriented discussion of pharmacological treatment alternatives. The 'change of life' in these talks is entirely conceptualised within a 'medical model'.
引用
收藏
页码:139 / 154
页数:16
相关论文
共 50 条
  • [1] Hormone replacement therapy in the menopause -: Structure and content of risk talk
    Hoffmann, M
    Lindh-Åstrand, L
    Ahlner, J
    Hammar, M
    Kjellgren, KI
    MATURITAS, 2005, 50 (01) : 8 - 18
  • [2] Hormone replacement therapy and cardiovascular risk
    Plu-Bureau, G
    THERAPIE, 1999, 54 (03): : 375 - 380
  • [3] Risk communication in consultations about hormone therapy in the menopause:: concordance in risk assessment and framing due to the context
    Hoffmann, M.
    Hammar, M.
    Kjellgren, K. I.
    Lindh-Astrand, L.
    Ahlner, J.
    CLIMACTERIC, 2006, 9 (05) : 347 - 354
  • [4] The replacement of the replacement in menopause: hormone therapy, controversies, truth and risk
    Burrell, Beverley A.
    NURSING INQUIRY, 2009, 16 (03) : 212 - 222
  • [6] Hormone replacement therapy and stroke
    Billeci, Antonia M. R.
    Paciaroni, Maurizio
    Caso, Valeria
    Agnelli, Giancarlo
    CURRENT VASCULAR PHARMACOLOGY, 2008, 6 (02) : 112 - 123
  • [7] Risk of stroke among users of hormone replacement therapy
    Oger, E
    Scarabin, PY
    ANNALES D ENDOCRINOLOGIE, 1999, 60 (03) : 232 - 241
  • [8] Hormone replacement therapy in a risk-benefit perspective
    Daly, E
    Vessey, MP
    Barlow, D
    Gray, A
    McPherson, K
    Roche, M
    MATURITAS, 1996, 23 (02) : 247 - 259
  • [9] Hormone replacement therapy and stroke: risk, protection or no effect?
    Paganini-Hill, A
    MATURITAS, 2001, 38 (03) : 243 - 261
  • [10] Hormone replacement therapy and breast cancer risk in California
    Coombs, NJ
    Taylor, R
    Wilcken, N
    Fiorica, J
    Boyages, J
    BREAST JOURNAL, 2005, 11 (06) : 410 - 415